Jazz Pharmaceuticals JAZZ Sleep — Revenue from Contract with Customer, Excluding Assessed Tax
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's sleep — revenue from contract with customer, excluding assessed tax.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's sleep — revenue from contract with customer, excluding assessed tax?
- Jazz Pharmaceuticals (JAZZ) reported sleep — revenue from contract with customer, excluding assessed tax of $439.4M in Q1 2026.
- What does sleep — revenue from contract with customer, excluding assessed tax mean?
- The total net sales generated from the company's sleep disorder medication portfolio.
- How do you interpret sleep — revenue from contract with customer, excluding assessed tax?
- An increase indicates growing market demand, successful commercial execution, or expanded patient access for sleep disorder treatments. A decrease may signal increased competition, patent expirations, or shifts in prescribing patterns.
- How does sleep — revenue from contract with customer, excluding assessed tax compare across companies?
- Comparable to revenue segments for specialized neuroscience or CNS (Central Nervous System) franchises at other biopharmaceutical companies, often benchmarked against product-specific growth rates in the sleep disorder market.